IFLR1000

Covis Pharma $350 million financing

13/12/2018
Financing
Select tab

$ 350 million

Completed

13/12/2018

Overview:

  • Swiss pharmaceutical company Covis Pharma undertook £350 million senior credit facility to finance the acquisition of rights for Alvesco, Omnaris and Zetonna drugs from AstraZeneca. 
  • Alvesco is used to treat persistent asthma, whereas Omnaris and Zetonna is used to treat nasal symptoms associated with rhinitis.

Rajeeb Gurung - Researcher

Jurisdiction:

Switzerland

Deal type:

Financing

Practice area:

Banking

Industry sector:

Pharmaceuticals and life sciences

Firms:
Linklaters

Party: Covis Pharma (Borrower)

Lowenstein Sandler

Party: Covis Pharma (Borrower)

Loyens & Loeff

Party: Capital One (Lead arranger)

Lawyers: Judith Raijmakers, Martijn Schoonewille

Milbank

Party: Syndicate of lenders (Lender)

Osler Hoskin & Harcourt

Party: Syndicate of lenders (Lender)

Torys

Party: Covis Pharma (Borrower)

Weidema van Tol

Party: Covis Pharma (Borrower)

Related deals